Drugs / Recombinant Coagulation Factor VIII Injection
Recombinant Coagulation Factor VIII Injection
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04060836 | May 2019 → Mar 2020 | hemophilia A | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Coagulation Factor VIII Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04060836 ↗ |
| Modality | Protein / enzyme biologic | “A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.” NCT04060836 ↗ |